News | News By Subject | News by Disease News By Date | Search News

Testosterone replacement News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Repros Therapeutics (RPRX) to Ditch Efforts to Seek Approval of Testosterone Drug in the U.S. if Key Study Fails     4/15/2016
Embattled Acerus (TRLPF) Loses U.S. Distribution Deal for Natesto With Endo International (ENDP)     12/31/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Lipocine Inc. (LPCN) Testosterone Therapy Meets Phase 3 Goals     9/24/2014
FDA Panel Denies Clarus Therapeutics' Oral Testosterone Drug Rextoro     9/19/2014
AbbVie (ABBV), Teva Pharmaceutical Industries Limited (TEVA) Illegally Blocked Generic Version Of AndroGel: Federal Trade Commission     9/9/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study     8/28/2014
25 Medical Societies Petition JAMA To Retract Misleading Testosterone Study     4/10/2014
Clarus Therapeutics Touts Phase 3 Success for Oral Testosterone Replacement Therapy     9/25/2012
BioSante Pharmaceuticals, Inc. (BPAX), Teva Pharmaceutical Industries Limited (TEVA) Surge as FDA OKs Testosterone Gel     2/16/2012
FDA Seeks Another Trial On Repros Therapeutics Inc. (RPRX) Testosterone Drug, Androxal     11/10/2010
Endo Pharmaceuticals (ENDP) Says FDA Extends Review Date for Testosterone Treatment     9/3/2009
Watson Pharmaceuticals, Inc. (WPI) Receives FDA Approval For Testosterone Gel Product     1/30/2006
P&G Pharmaceuticals, Inc. (PG) Release: Landmark Clinical Study Shows Female Testosterone Patch Significantly Improved Sexual Desire In Surgically Menopausal Women     5/4/2004

News from Around the Web

Press Releases
Acrux (ACR) Plunges After Deal With Eli Lilly (LLY) Is Terminated     9/6/2017
Clarus Therapeutics Re-Submits JATENZO NDA Following Positive Results Of inTUne Trial     6/26/2017
Lipocine (LPCN) Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results For LPCN 1021, Oral Testosterone Candidate     6/20/2017
Lipocine (LPCN) Completes Enrollment In The LPCN 1021 Fixed Dose Clinical Trials     4/24/2017
Acerus (TRLPF) Announces NATESTO Regulatory Filing in South Korea     4/6/2017
Lipocine (LPCN) To Initiate Dosing Validation Study For LPCN 1021, Oral Testosterone Replacement Product Candidate     12/5/2016
Lipocine (LPCN) Completes Post Action Meeting With FDA For LPCN 1021 New Drug Application     10/17/2016
Clarus Therapeutics Provides Update On Patent Infringement Lawsuit Against Lipocine (LPCN)'s Oral Product For Testosterone Replacement Therapy     10/13/2016
Repros Therapeutics (RPRX) Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities     10/6/2016
Lipocine (LPCN) Announces Positive Top-Line Phase IIb Study Results For LPCN 1111, A Next Generation Oral Testosterone Replacement Therapy     9/26/2016
Embattled Acerus (TRLPF) Loses U.S. Distribution Deal for Natesto With Endo International (ENDP)     12/31/2015
Clarus Therapeutics Seeks Injunction Against The Marketing Of Lipocine Inc. (LPCN)'s Oral Product For Testosterone Replacement Therapy (LPCN 1021)     11/3/2015
Lipocine Inc. (LPCN) Submits New Drug Application To FDA For Its Oral Testosterone Replacement Product Candidate, LPCN 1021     8/31/2015
Trimel Pharmaceuticals (TRL.TO) Announces Second Quarter 2015 Financial Results And Highlights     8/5/2015
Lipocine Inc. (LPCN)'s Oral Testosterone Well Tolerated In Phase III Study     6/30/2015